Common TitleINNOVE
Official Title A Randomized, Open-label Study Evaluating the Antiviral Activity and Safety of 3 Month Fuzeon Induction With an Optimized Background Antiretroviral Regimen Versus OB Alone, in Fuzeon-naive HIV-1 Infected Patients With Virological Failure.
Phase Phase II
ClinicalTrials.gov NCT00615134
Treatments
Enfuvirtide
Enfuvirtide
Tradename:FuzeonOther Names:T-20Class:Entry InhibitorsCategories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryHoffmann-La Roche
References
- Morand-Joubert L, Ghosn J, Delaugerre C, et al. Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study. J Med Virol. 2012;84:1710-8.